Finance

Lists
KAEF:IDX
Kimia Farma (Persero) Tbk PT
IDR 440.00
0.00%
(0.00) 1D
Sep 15, 4:09:09 PM GMT+7  ·   IDR
All symbols
SymbolPriceChange% Change
Generating top insights for KAEF...
Open
IDR 442
High
IDR 444
Low
IDR 434
Mkt. cap
2.45T
Avg. vol.
3.71M
Volume
922.80K
52-wk high
IDR 785
52-wk low
IDR 380
EPS
-IDR 77
Shares outstanding
5.57B
No. of employees
9K
Open
IDR 442
High
IDR 444
Low
IDR 434
Mkt. cap
2.45T
Avg. vol.
3.71M
Volume
922.80K
52-wk high
IDR 785
52-wk low
IDR 380
EPS
-IDR 77
Shares outstanding
5.57B
No. of employees
9K
Profile
PT Kimia Farma Tbk is an Indonesian pharmaceutical producer and distributor in Indonesia. It is based in Jakarta. Wikipedia
About Kimia Farma (Persero) Tbk PT
CEO-
Employees9.36K
FoundedAug 16, 1971
Headquarters-
SectorPharmaceutical industry
Websitekimiafarma.co.id
Previous reportsAll values in IDR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in IDR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.64T
2.22T
2.03T
2.67T
Cost of goods sold
1.85T
1.56T
1.29T
1.86T
Cost of revenue
1.85T
1.56T
1.29T
1.86T
Research and development expenses
5.03B
7.54B
3.20B
10.39B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
709.79B
663.87B
640.94B
620.33B
Operating expense
766.80B
877.17B
669.20B
722.39B
Total operating expenses
2.62T
2.44T
1.96T
2.59T
Operating income
23.59B
-222.99B
67.93B
84.77B
Other non operating income
-2.92B
173.66B
159.00B
-26.56B
EBT including unusual items
-94.33B
-223.75B
127.96B
-60.16B
EBT excluding unusual items
-93.48B
-260.76B
127.95B
-60.19B
Income tax expense
4.17B
-14.50B
4.32B
9.40B
Effective tax rate
-4.42%
6.48%
3.37%
-15.62%
Other operating expenses
-37.43B
-36.20B
-12.78B
-9.74B
Net income
-84.72B
-155.23B
74.45B
-64.12B
Net profit margin
-3.21%
-7.01%
3.67%
-2.40%
Earnings per share
-
-
-
-
Interest and investment income
2.65B
10.77B
2.87B
8.13B
Interest expense
-115.65B
-221.53B
-110.15B
-125.81B
Net interest expenses
-112.99B
-210.75B
-107.28B
-117.68B
Depreciation and amortization charges
89.41B
175.98B
37.85B
101.42B
EBITDA
105.34B
-86.40B
125.64B
165.62B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps